DPP-4i and SGLT2i combined with intensive insulin therapy significantly reduce glycemic variability in type 2 diabetes.
Effects of intensive insulin therapy combined with non-insulin antihyperglycemic agents on glycemic control, variability, and metabolic outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Abstract
Combining DPP-4i with intensive insulin therapy reduced MAGE and LAGE, while SGLT2i reduced SDBG in type 2 diabetes patients, improving glycemic control.
